These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 24929222)

  • 1. Multidrug resistance in cancer or inefficacy of neuroactive agents: innovative strategies to inhibit or circumvent the active efflux transporters selectively.
    Pavan B; Paganetto G; Rossi D; Dalpiaz A
    Drug Discov Today; 2014 Oct; 19(10):1563-71. PubMed ID: 24929222
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Overcoming drug efflux-based multidrug resistance in cancer with nanotechnology.
    Xue X; Liang XJ
    Chin J Cancer; 2012 Feb; 31(2):100-9. PubMed ID: 22237039
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Overcoming ABC transporter-mediated multidrug resistance: Molecular mechanisms and novel therapeutic drug strategies.
    Li W; Zhang H; Assaraf YG; Zhao K; Xu X; Xie J; Yang DH; Chen ZS
    Drug Resist Updat; 2016 Jul; 27():14-29. PubMed ID: 27449595
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Reversal of multidrug resistance by the inhibition of ATP-binding cassette pumps employing "Generally Recognized As Safe" (GRAS) nanopharmaceuticals: A review.
    Sosnik A
    Adv Drug Deliv Rev; 2013 Nov; 65(13-14):1828-51. PubMed ID: 24055628
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Self-assembling nanoparticles encapsulating zoledronic acid revert multidrug resistance in cancer cells.
    Kopecka J; Porto S; Lusa S; Gazzano E; Salzano G; Giordano A; Desiderio V; Ghigo D; Caraglia M; De Rosa G; Riganti C
    Oncotarget; 2015 Oct; 6(31):31461-78. PubMed ID: 26372812
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Nanoparticle delivery of anticancer drugs overcomes multidrug resistance in breast cancer.
    Yuan Y; Cai T; Xia X; Zhang R; Chiba P; Cai Y
    Drug Deliv; 2016 Nov; 23(9):3350-3357. PubMed ID: 27098896
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Revisiting the ABCs of multidrug resistance in cancer chemotherapy.
    Tiwari AK; Sodani K; Dai CL; Ashby CR; Chen ZS
    Curr Pharm Biotechnol; 2011 Apr; 12(4):570-94. PubMed ID: 21118094
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Combating P-glycoprotein-mediated multidrug resistance using therapeutic nanoparticles.
    Zhang Q; Li F
    Curr Pharm Des; 2013; 19(37):6655-66. PubMed ID: 23621532
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Advances in the targeting ATP-binding cassette transporters to overcome tumor multi-drug resistance].
    Wei N; Sun H; Liu GT
    Yao Xue Xue Bao; 2010 Oct; 45(10):1205-11. PubMed ID: 21348297
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tackling multidrug resistance mediated by efflux transporters in tumor-initiating cells.
    McIntosh K; Balch C; Tiwari AK
    Expert Opin Drug Metab Toxicol; 2016 Jun; 12(6):633-44. PubMed ID: 27116192
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Co-delivery strategies to overcome multidrug resistance in ovarian cancer.
    Khan IU; Khan RU; Asif H; Alamgeer ; Khalid SH; Asghar S; Saleem M; Shah KU; Shah SU; Rizvi SAA; Shahzad Y
    Int J Pharm; 2017 Nov; 533(1):111-124. PubMed ID: 28947245
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Nanomedicine to overcome cancer multidrug resistance.
    Yang X; Yi C; Luo N; Gong C
    Curr Drug Metab; 2014; 15(6):632-49. PubMed ID: 25255871
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Heterocyclic cyclohexanone monocarbonyl analogs of curcumin can inhibit the activity of ATP-binding cassette transporters in cancer multidrug resistance.
    Revalde JL; Li Y; Hawkins BC; Rosengren RJ; Paxton JW
    Biochem Pharmacol; 2015 Feb; 93(3):305-17. PubMed ID: 25543853
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Relevance of multidrug resistance in the age of targeted therapy.
    Türk D; Szakács G
    Curr Opin Drug Discov Devel; 2009 Mar; 12(2):246-52. PubMed ID: 19333870
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Novel tetrahydroisoquinolin-ethyl-phenylamine based multidrug resistance inhibitors with broad-spectrum modulating properties.
    Jekerle V; Klinkhammer W; Reilly RM; Piquette-Miller M; Wiese M
    Cancer Chemother Pharmacol; 2007 Jan; 59(1):61-9. PubMed ID: 16636798
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Strategies for overcoming ABC-transporters-mediated multidrug resistance (MDR) of tumor cells.
    Borowski E; Bontemps-Gracz MM; Piwkowska A
    Acta Biochim Pol; 2005; 52(3):609-27. PubMed ID: 16175236
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Biofunctionalized polymer-lipid supported mesoporous silica nanoparticles for release of chemotherapeutics in multidrug resistant cancer cells.
    Zhang X; Li F; Guo S; Chen X; Wang X; Li J; Gan Y
    Biomaterials; 2014 Apr; 35(11):3650-65. PubMed ID: 24462359
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical management of recurrent breast cancer: development of multidrug resistance (MDR) and strategies to circumvent it.
    Hait WN; Yang JM
    Semin Oncol; 2005 Dec; 32(6 Suppl 7):S16-21. PubMed ID: 16360718
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Elacridar enhances the cytotoxic effects of sunitinib and prevents multidrug resistance in renal carcinoma cells.
    Sato H; Siddig S; Uzu M; Suzuki S; Nomura Y; Kashiba T; Gushimiyagi K; Sekine Y; Uehara T; Arano Y; Yamaura K; Ueno K
    Eur J Pharmacol; 2015 Jan; 746():258-66. PubMed ID: 25455500
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Reversal of P-gp and BCRP-mediated MDR by tariquidar derivatives.
    Li XQ; Wang L; Lei Y; Hu T; Zhang FL; Cho CH; To KK
    Eur J Med Chem; 2015 Aug; 101():560-72. PubMed ID: 26197160
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.